Fomivirsen: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Protected "Fomivirsen": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))
 
Rabin Bista (talk | contribs)
nocaptcha, Administrators
4,526 edits
No edit summary
 
Line 1: Line 1:
{{Drugbox|
{{Drugbox
|IUPAC_name =  
| Verifiedfields = changed
| image=Fomivirsen composite.png
| verifiedrevid = 407239066
| IUPAC_name =
| image = Fomiversen Wiki Str.png
 
| width = 250
| width = 250
| CAS_number=160369-77-7
 
| ATC_prefix=S01
<!--Clinical data-->
| ATC_suffix=AD08
| tradename = 
| ATC_supplemental=
| Drugs.com = {{drugs.com|CONS|fomivirsen}}
| PubChem=
| pregnancy_AU = B2
| DrugBank=
| legal_status = 
| C = 204 | H = 263 | N = 63 | O = 114 | P = 20 | S = 20
| routes_of_administration = Intravitreal [[injection (medicine)|injection]]
 
<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| excretion = 
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 160369-77-7
| ATC_prefix = S01
| ATC_suffix = AD08
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02736
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201688
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = NA
 
<!--Chemical data-->
| C=204 | H=263 | N=63 | O=114 | P=20 | S=20  
| molecular_weight = 6682.4 g/mol
| molecular_weight = 6682.4 g/mol
| bioavailability=
| metabolism =
| elimination_half-life=
| excretion = 
| pregnancy_category = B2
| legal_status =
| routes_of_administration= Intravitreal [[injection (medicine)|injection]]
}}
}}
'''Fomivirsen''' (brand name '''Vitravene''') is an [[antiviral drug]]. It is used in the treatment of [[cytomegalovirus retinitis]] (CMV) in [[immunocompromised]] patients, including those with [[AIDS]].
__NOTOC__
{{SI}}
{{CMG}}
== Overview ==
 
'''Fomivirsen''' (brand name '''Vitravene''') is an [[antiviral drug]]. It is used in the treatment of [[cytomegalovirus retinitis]] (CMV) in [[immunocompromised]] patients, including those with [[AIDS]]. It was licenced by the FDA for CMV in Aug 1998.
 
It is a synthetic 21 member [[oligonucleotide]] with [[thiophosphate|phosphorothioate]] linkages (which are resistant to degradation by [[nuclease]]s) and has the sequence:


It is an [[oligonucleotide]] that blocks translation of viral mRNA by binding to a coding segment of a key CMV gene. It was the first [[antisense]] antiviral approved by the FDA.
* 5'-GCG TTT GCT CTT CTT CTT GCG-3'


It is available as an intraocular injection in a concentration of 6.6 mg/ml<sup>1</sup>
== Mechanism ==


It is an [[oligonucleotide]]<ref name="pmid9559825">{{cite journal |author=Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM |title=Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922) |journal=Antimicrob. Agents Chemother. |volume=42 |issue=4 |pages=971–3 |date=April 1998 |pmid=9559825 |pmc=105584 |doi= |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=9559825}}</ref> that blocks [[Translation (genetics)|translation]] of viral mRNA by binding to the complementary sequence of the mRNA transcribed from the coding segment of a key CMV gene. It was the first [[antisense therapy|antisense]] antiviral approved by the FDA.<ref name="pmid9182327">{{cite journal | author = Roush W | title = Antisense aims for a renaissance | journal = Science | volume = 276 | issue = 5316 | pages = 1192–3 |date=May 1997 | pmid = 9182327 | doi = 10.1126/science.276.5316.1192 | url =  }}</ref>


== References ==
== Administration ==
1. Katzung, BG. Basic and Clinical Pharmacology 10th ed., 2007. McGraw-Hill Co., Inc.


It is available as an intraocular injection in a concentration of 6.6 mg/mL.<ref name="isbn0-07-145153-6">{{cite book | author = Katzung, Bertram G. | authorlink = | editor = | others = | title = Basic and Clinical Pharmacology | edition = 10th | language = | publisher = McGraw-Hill Medical Publishing Division | location = New York | year = 2006 | origyear = | pages = 817 | quote = | isbn = 0-07-145153-6 | oclc = | doi = | url = | accessdate = }}</ref>


==See also==
==See also==
* [[retinitis]]
* [[retinitis]]
== References ==
{{Reflist|2}}
== Further reading ==
{{refbegin | 2}}
* {{cite journal | author = | title = Fomivirsen | journal = Drugs Today (Barc) | volume = 37 | issue = 4 | pages = 245–255 | year = 2001 | pmid = 12768225 | last1 = Grillone | first1 = LR | last2 = Lanz | first2 = R}}
* {{cite journal | author = Geary R, Henry S, Grillone L | title = Fomivirsen: clinical pharmacology and potential drug interactions | journal = Clin Pharmacokinet | volume = 41 | issue = 4 | pages = 255–60 | year = 2002 | pmid = 11978144 | doi=10.2165/00003088-200241040-00002}}
* {{cite journal | author = | title = Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS | journal = Am J Ophthalmol | volume = 133 | issue = 4 | pages = 475–83 | year = 2002 | pmid = 11931781| doi = 10.1016/S0002-9394(02)01326-0 | last1 = Vitravene Study | first1 = Group}}
* {{cite journal | author = Roehr B | title = Fomivirsen approved for CMV retinitis | journal = J Int Assoc Physicians AIDS Care | volume = 4 | issue = 10 | pages = 14–6 | year = 1998 | pmid = 11365956}}
{{refend}}


==External links==
==External links==
* [http://www.rxlist.com/cgi/generic2/fomivirsen.htm Diagram]
* {{MedlinePlusDrugInfo|uspdi|203675}}
* {{MedlinePlusDrugInfo|uspdi|203675}}
* {{DiseasesDB|31313}}
* {{DiseasesDB|31313}}
* {{cite journal | author = | title = Fomivirsen. | journal = Drugs Today (Barc) | volume = 37 | issue = 4 | pages = 245-255 | year = 2001 | id = PMID 12768225}}
* {{cite web | url = http://www.rxlist.com/cgi/generic2/fomivirsen.htm | title = Vitravene (Fomivirsen) Drug Information: Uses, Side Effects, Drug Interactions and Warning | author = | authorlink = | coauthors = | date = 2004-12-08| format = | work = | publisher = RxList  | pages = | language = | archiveurl = | archivedate = | quote = | accessdate = 2009-05-20}}
* {{cite journal | author = Geary R, Henry S, Grillone L | title = Fomivirsen: clinical pharmacology and potential drug interactions. | journal = Clin Pharmacokinet | volume = 41 | issue = 4 | pages = 255-60 | year = 2002 | id = PMID 11978144}}
* {{cite journal | author = | title = Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. | journal = Am J Ophthalmol | volume = 133 | issue = 4 | pages = 475-83 | year = 2002 | id = PMID 11931781}}
* {{cite journal | author = Roehr B | title = Fomivirsen approved for CMV retinitis. | journal = J Int Assoc Physicians AIDS Care | volume = 4 | issue = 10 | pages = 14-6 | year = 1998 | id = PMID 11365956}}


{{antimicrobial-stub}}
{{Antivirals}}
{{Antivirals}}
{{antimicrobial-stub}}
 
[[Category:Antivirals]]
[[Category:drug]]
[[Category:Anti-herpes virus drugs]]
[[Category:Orphan drugs]]
[[Category:Orphan drugs]]
[[de:Fomivirsen]]

Latest revision as of 16:19, 13 April 2015

Fomivirsen
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
Routes of
administration		Intravitreal injection
ATC code
Identifiers
CAS Number
ChemSpider
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC204H263N63O114P20S20
Molar mass6682.4 g/mol
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Fomivirsen

Articles

Most recent articles on Fomivirsen

Most cited articles on Fomivirsen

Review articles on Fomivirsen

Articles on Fomivirsen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fomivirsen

Images of Fomivirsen

Photos of Fomivirsen

Podcasts & MP3s on Fomivirsen

Videos on Fomivirsen

Evidence Based Medicine

Cochrane Collaboration on Fomivirsen

Bandolier on Fomivirsen

TRIP on Fomivirsen

Clinical Trials

Ongoing Trials on Fomivirsen at Clinical Trials.gov

Trial results on Fomivirsen

Clinical Trials on Fomivirsen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fomivirsen

NICE Guidance on Fomivirsen

NHS PRODIGY Guidance

FDA on Fomivirsen

CDC on Fomivirsen

Books

Books on Fomivirsen

News

Fomivirsen in the news

Be alerted to news on Fomivirsen

News trends on Fomivirsen

Commentary

Blogs on Fomivirsen

Definitions

Definitions of Fomivirsen

Patient Resources / Community

Patient resources on Fomivirsen

Discussion groups on Fomivirsen

Patient Handouts on Fomivirsen

Directions to Hospitals Treating Fomivirsen

Risk calculators and risk factors for Fomivirsen

Healthcare Provider Resources

Symptoms of Fomivirsen

Causes & Risk Factors for Fomivirsen

Diagnostic studies for Fomivirsen

Treatment of Fomivirsen

Continuing Medical Education (CME)

CME Programs on Fomivirsen

International

Fomivirsen en Espanol

Fomivirsen en Francais

Business

Fomivirsen in the Marketplace

Patents on Fomivirsen

Experimental / Informatics

List of terms related to Fomivirsen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fomivirsen (brand name Vitravene) is an antiviral drug. It is used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. It was licenced by the FDA for CMV in Aug 1998.

It is a synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases) and has the sequence:

  • 5'-GCG TTT GCT CTT CTT CTT GCG-3'

Mechanism

It is an oligonucleotide[1] that blocks translation of viral mRNA by binding to the complementary sequence of the mRNA transcribed from the coding segment of a key CMV gene. It was the first antisense antiviral approved by the FDA.[2]

Administration

It is available as an intraocular injection in a concentration of 6.6 mg/mL.[3]

See also

References

  1. ↑ Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (April 1998). "Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922)". Antimicrob. Agents Chemother. 42 (4): 971–3. PMC 105584. PMID 9559825.
  2. ↑ Roush W (May 1997). "Antisense aims for a renaissance". Science. 276 (5316): 1192–3. doi:10.1126/science.276.5316.1192. PMID 9182327.
  3. ↑ Katzung, Bertram G. (2006). Basic and Clinical Pharmacology (10th ed.). New York: McGraw-Hill Medical Publishing Division. p. 817. ISBN 0-07-145153-6.

Further reading

  • Grillone, LR; Lanz, R (2001). "Fomivirsen". Drugs Today (Barc). 37 (4): 245–255. PMID 12768225.
  • Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clin Pharmacokinet. 41 (4): 255–60. doi:10.2165/00003088-200241040-00002. PMID 11978144.
  • Vitravene Study, Group (2002). "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". Am J Ophthalmol. 133 (4): 475–83. doi:10.1016/S0002-9394(02)01326-0. PMID 11931781.
  • Roehr B (1998). "Fomivirsen approved for CMV retinitis". J Int Assoc Physicians AIDS Care. 4 (10): 14–6. PMID 11365956.

External links


Pills  This antimicrobial-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://www.wikidoc.org/index.php?title=Fomivirsen&oldid=1086801"